The American Journal of Medicine
Volume 122, Issue 7 , Pages 599-604 , July 2009

Osteoporosis in Inflammatory Bowel Disease

  • Tauseef Ali, MD

      Affiliations

    • Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City
    • Section of Digestive Diseases and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City
    • ,
  • David Lam, MD

      Affiliations

    • Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City
    • ,
  • Michael S. Bronze, MD

      Affiliations

    • Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City
    • ,
  • Mary Beth Humphrey, MD, PhD

      Affiliations

    • Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City
    • Section of Rheumatology, Immunology and Allergy, University of Oklahoma Health Sciences Center, Oklahoma City
    • Corresponding Author InformationRequests for reprints should be addressed to Mary Beth Humphrey, MD, PhD, Department of Medicine, University of Oklahoma Health Sciences Center, 975 N.E. 10th St., BRC 209, Oklahoma City, OK 73104

References 

  1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (Report of a WHO Study Group). World Health Organ Tech Rep Ser. 1994;843:1–129
  2. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut. 1987;28(4):410–415
  3. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40(2):228–233
  4. Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93(9):1483–1490
  5. Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003;15(8):857–864
  6. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124(3):795–841
  7. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996;39(11):1791–1801
  8. van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383–1389
  9. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–787
  10. Neurath MF, Pettersson S. Predominant role of NF-kappa B p65 in the pathogenesis of chronic intestinal inflammation. Immunobiology. 1997;198(1-3):91–98
  11. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336(15):1066–1071
  12. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest. 2002;110(10):1419–1427
  13. Manolagas SC. The role of IL-6 type cytokines and their receptors in bone. Ann N Y Acad Sci. 1998;840:194–204
  14. Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000;119(4):909–920
  15. Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep. 2007;5(3):98–104
  16. Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm Bowel Dis. 2005;11(4):325–330
  17. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005;54(4):479–487
  18. Hofbauer LC, Lacey DL, Dunstan CR, et al. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 1999;25(3):255–259
  19. Miheller P, Muzes G, Racz K, et al. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm Bowel Dis. 2007;13(11):1379–1384
  20. Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther. 2004;20(6):607–614
  21. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol. 2006;40(1):55–63
  22. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89(5):747–754
  23. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–523
  24. Mbalaviele G, Sheikh S, Stains JP, et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem. 2005;94(2):403–418
  25. Ohnaka K, Tanabe M, Kawate H, et al. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun. 2005;329(1):177–181
  26. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008;4(2):80–90
  27. Silvennoinen J, Lamberg-Allardt C, Karkkainen M, et al. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med. 1996;240(5):285–292
  28. Cashman KD, Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease?. Eur J Gastroenterol Hepatol. 2003;15(6):607–613
  29. McCarthy D, Duggan P, O'Brien M, et al. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment Pharmacol Ther. 2005;21(9):1073–1083
  30. Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr. 2006;60(7):889–896
  31. Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol. 2004;99(11):2178–2185
  32. Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone. 1996;18(5):487–488
  33. Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008;11(4):473–477
  34. Kornbluth A, Hayes M, Feldman S, et al. Do guidelines matter? (Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria). Am J Gastroenterol. 2006;101(7):1546–1550
  35. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008;
  36. Lewis NR, Scott BB. Guidelines for Osteoporosis in Inflammatory Bowel Disease and Coeliac Disease. London: British Society of Gastroenterology; 2007;
  37. Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol. 2006;101(1):119–123
  38. Palomba S, Manguso F, Orio F, et al. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Menopause. 2008;15(4 Pt 1):730–736
  39. Chestnut CH. Calcitonin in the prevention and treatment of osteoporosis. Osteoporos Int. 1993;3(Suppl 1):206–207
  40. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333
  41. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337(23):1641–1647
  42. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trialMultiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–645
  43. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441
  44. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int. 2008;82(4):249–257
  45. Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol. Feb 2005;3(2):113–121
  46. Reffitt DM, Meenan J, Sanderson JD, et al. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15(12):1267–1273
  47. Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther. 2004;20(8):851–857
  48. Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci. 2006;1068:543–556

 Funding: Dr. Humphrey received funding from US Department of Veterans Affairs.

 Conflict of Interest: None.

 Authorship: All authors contributed to writing this manuscript.

PII: S0002-9343(09)00162-4

doi: 10.1016/j.amjmed.2009.01.022

The American Journal of Medicine
Volume 122, Issue 7 , Pages 599-604 , July 2009

Article Tools